News and Comments

KITE Pharma: The Risk Versus the Reward

Prohost Biotech - Tuesday, May 09, 2017

Indeed, Saving One life is Important. Yet, Important Too is Saving Many Lives

The Risk Vs. The Reward

We keep repeating that the CAR-T treatment is created to stay, not because somebody loves the firms developing the CAR-T immunotherapy, but because this novel approach to cancer is saving the lives of the condemned. In addition, many reasons exist that make oncologists and regulators believe that the treatment will be perfected and will save more lives than any statistics’ past history would tell.  

The question is not about one death, but about how many condemned late stage cancer patients have been given hope, or saved after all other treatments, marketed and investigational have failed.

Indeed, the FDA will be involved, trying to pinpoint the cause, or causes of the one death from among 300 people who were treated with Kite’s (KITE) CAR-T approach. The FDA, the NIH, the academic oncology centers in the top universities in the world will be also looking into the death case. They will do, not to stop the product, not to deny approving it, but as part of their attempts to find a way to improve CAR-T safety, in addition to its efficacy. These attempts are ongoing and we wrote several articles about them and about the academic institutions’ collaboration with the developing firms in order to prevent the occurrence of the cytokine release syndrome and also to enable the CAR-T to be effective in treating solid tumors in addition to hematologic malignancies.

The regulatory agencies along with top research institutions, universities and serious drug developers – all recognize the value of every human life. They all do whatever they can to prevent loss of life. Unfortunately, some cancer cases are so advanced that the best existing treatments might not work as they do in other advanced stage cancers. Also, the people with very advanced cancer who took several treatments might not be tolerate to tolerate their adverse effects. All cancer treatments have numerous adverse effects with some extremely toxic, however, when the rewards outweigh the risk the products are approved for marketing.  

To be continued

Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our 'opinions' and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal.



Comments
Post has no comments.
Post a Comment




Captcha Image

Trackback Link
http://www.prohostbiotech.com/BlogRetrieve.aspx?BlogID=8883&PostID=1496033&A=Trackback
Trackbacks
Post has no trackbacks.

Recent Postings


Archive


Tags

Epizyme (EPZM) PTC Therapeutics (PTCT) GlycoMimetics (GLYN) Telaprevir Intercept (ICPT) Valeant Pharmaceuticals International (VRX) Spike Therapeutics (ONCE) Cytokinetics (CYTK) Dynavax (DVAX) ARCA (ABIO) NEKTAR (NKTR)) JUNO (JUNO) CRISPR Therapeutics (CRSP) Alder Biopharmaceuticals (ALDR) Regeneron (REGN) Prosensa (RNA) Bellicum (BLCM) Agenus (AGEN) Xoma (XOMA) C4 Therapeutics Auspex (ASPX) Velcade (bortezomib) Theravance (THRX) MODERNA IDERA (IDRA) Bristol-Myers Squibb (BMY) Ionis (IONS) Ocular Therapeutix (OCUL) Revlimid (lenolidamide) Advaxis (ADXS) GlaxoSmithKline (GSK) LEXICON (LXRX) JOUNCE THERAPEUTICS (JNCE) Sanofi (SNA) Array Pharmaceuticals (ARRY) Galena (GALE) SYNTA (SNTA) OncoCyte (OCX) Sequenom (SQNM) Prolor Biotech (PBTH) AERIE PHARMACEUTICALS Genentech Jazz Pharmaceuticals (JAZZ) ImmunoGen (IMGN) Human Genome Sciences (HGSI) Theravance Bio Pharma (TBPH) Human Longevity (HLI) Sarepta (SRPT) INNOVIVA (INVA) Abbott Laboratories (ABT) Merck (MRK) Editas (EDIT) Inovio (INO) ADVENTRIX (ANX) Intrexon (XON) VANDA (VNDA) Akebia Therapeutics (AKAB) NOVOCURE (NVCR) Anadys (ANDS) Vertex (VRTX) Mirati Therapeutics (MRTX) Benlysta (belimumab) Exelixis (EXEL) AGOS (ARGS) galapagos (GLPG) TOKAI (TKAOI) Sanofi (SNY) SERES THERAPEUTICS (MCRB) Gilead (GILD) RenenxBio (RGNX) KITE (KITE) Aimmune Therapeutics (AIMT) Elan (ELN) Trastuzumab-DM1 Micromet (MITI) AstraZeneca (AZN) ABBVIE (ABBV) NEUROCRINE (NBIX) Illumina (ILMN) Biogen Idec (BIIB) Intermune (ITMN) Vitae Pharmaceuticals (VTAE) Herceptin PORTOLA (PTLA) Anacor (ANAC) Tysabri Endometrial Cancer Rapamune Ridaforolimus Zerenex NANTKWEST (NK) Incyte (INCY) Ariad (ARIA) ARGOS (ARGS) Ziofpharm (ZIOP) OSI (OSIP) BIOMARIN (BMRN) CompuGen (CGEN) Alnylam (ALNY) Dendreon (DNDN) Onyx (ONXX) Amgen (AMGN) GUARDIAN HEALTH Agenus (AGEN Roche (RHHBY) KERYX (KERX) ISIS (ISIS) Seattle Genetics (SGEN) HALOZYME (HALO) REGULUS (RGLS) Multiple Myeloma Adaptimmune (ADAP) Sangamo (SGMO) Pluristem (PSTI) Global Cell Therapeutics (GBT) Roche (ROCHE) ZALTRAP™ Biocryst (BCRX) Sanofi-Aventis (SAN) SUNESIS PHARMACEUTICALS (SNSS) ACADIA (ACAD) Idenix (IDIX) CEMPRA (CEMP)